Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
47.17
-0.40 (-0.84%)
At close: Feb 4, 2025, 4:00 PM
47.50
+0.33 (0.70%)
Pre-market: Feb 5, 2025, 4:49 AM EST
Guardant Health Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Guardant Health stock have an average target of 42.57, with a low estimate of 32 and a high estimate of 60. The average target predicts a decrease of -9.75% from the current stock price of 47.17.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Guardant Health stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 10 | 10 | 10 |
| Buy | 6 | 6 | 6 | 6 | 6 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 17 | 17 | 17 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $36 → $49 | Strong Buy | Maintains | $36 → $49 | +3.88% | Jan 28, 2025 |
| Barclays | Barclays | Buy Initiates $60 | Buy | Initiates | $60 | +27.20% | Jan 23, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Jan 22, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $48 → $50 | Buy | Maintains | $48 → $50 | +6.00% | Nov 7, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $32 → $36 | Strong Buy | Maintains | $32 → $36 | -23.68% | Nov 7, 2024 |
Financial Forecast
Revenue This Year
746.67M
from 563.95M
Increased by 32.40%
Revenue Next Year
873.01M
from 746.67M
Increased by 16.92%
EPS This Year
-3.52
from -4.28
EPS Next Year
-2.97
from -3.52
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 774.1M | 968.8M | 1.2B | |||
| Avg | 746.7M | 873.0M | 1.1B | |||
| Low | 707.3M | 800.0M | 882.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 37.3% | 29.8% | 33.1% | |||
| Avg | 32.4% | 16.9% | 20.6% | |||
| Low | 25.4% | 7.1% | 1.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -3.10 | -1.63 | -0.92 | |
| Avg | -3.52 | -2.97 | -2.39 | |
| Low | -3.61 | -4.00 | -4.40 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.